Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Depot vs Tablets in Chronic Schizophrenia
NCT00249223Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2000
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of risperidone in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Positive and Negative Syndrome Scale Total Score at 12 weeks. Started Jan 2000; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00249223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00249223.